SEMINAR: May 2022 – Is a PRO VALUE-able, When and How?

Dr. Feng Xie is a health economist whose research centers around economic evaluations conducted alongside clinical trials and based on models in the context of health technology assessment and coverage policy making. He is particularly interested in measuring and valuing patient-reported outcomes which is one of the most challenging parts in patient-centered health care research.

Patient-reported outcome (PRO) has become increasingly popular in the era of patient-centered health care and decision making. Multiple guidelines are available to provide useful guidance on the development of PRO instruments (e.g. FDA and EMA). However, there exist debates, controversies, and confusions about valuing PROs. This talk will walk through key concepts in an attempt to delineate some nuances in measuring and valuing PROs for clinical and economic evaluations.